Clinical Trials on NY-ESO-1 Positive Tumor Cells Present

Total 385 results

Hassane M. Zarour, MD
National Cancer Institute (NCI)

Completed

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

NY-ESO-1-expressing Tumors

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | EBV-Positive Neoplastic Cells Present | HLA-A*0201 Positive Cells Present | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Elevated WT1

United States
University Health Network, Toronto
Takara Bio Inc.

Active, not recruiting

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Melanoma | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Liver Cancer | Synovial Sarcoma | NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients

Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | HLA-A*0201 Positive Cells Present | COL6A3 Positive | PRAME Positive

United States
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

Neuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor

United States, Brazil
University of Washington
National Cancer Institute (NCI)

Withdrawn

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pfizer

Terminated

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White Cells

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells Present

United States
Center for International Blood and Marrow Transplant...
Patient-Centered Outcomes Research Institute; National Marrow Donor Program

Completed

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT

United States
Yusuf Menda
National Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...

Enrolling by invitation

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
University of Iowa
Novartis

Not yet recruiting

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Neuroendocrine Tumors | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
University Hospital, Strasbourg, France

Terminated

DECT Ventilation Imaging

For Oncologic Patients | Potentially Operable Lung Tumor | With a Recent (Less Than 1 Month) VQ Scan | For Lung Transplant Recipients | Single of Bilateral Lung Transplant | From 5 Months Onwards | With Recent (Less Than 1 Month) Respiratory Functional Explorations

France
Roswell Park Cancer Institute
Pfizer

Withdrawn

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Blasts 5 Percent or More of Peripheral Blood White Cells | Lymphoblasts... and other conditions

United States
University of Wisconsin, Madison

Not yet recruiting

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine Tumors | Somatostatin Receptor-positive Neuroendocrine Tumor

United States
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
Novartis Pharmaceuticals

Active, not recruiting

LUTATHERA Injection General Use Result Survey

Somatostatin Receptor-positive Neuroendocrine Tumor

Japan
University of Roma La Sapienza

Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (REBORN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin Lymphoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Terminated

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic... and other conditions

United States
AC Camargo Cancer Center

Recruiting

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer (HER2Cell)

Breast Neoplasms | HER2-positive Breast Cancer | Circulating Tumor Cell

Brazil
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
Institut Paoli-Calmettes

Recruiting

Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors (RFANET)

Neuroendocrine Tumor Grade 1 | Neuroendocrine Tumor of Pancreas (Disorder)

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

BRAF V600E Mutation Present | Papillary Craniopharyngioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Malignant Mesothelioma | CD30-Positive Neoplastic Cells Present

United States
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
University Hospital, Basel, Switzerland
University Hospital, Zürich; University Hospital Freiburg; Krebsforschung Schweiz... and other collaborators

Recruiting

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. (Lumed)

Thyroid Cancer, Medullary | Neuroendocrine Tumor of the Lung Grade 1 and 2 | Neuroendocrine Tumor of the Thymus Grade 1 and 2 | Neuroendocrine Tumor GEP Grade 1-3

Switzerland
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
AIPING ZHOU

Not yet recruiting

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1

China
University of Central Florida

Recruiting

Liquid Biopsy Collection Study

Circulating Tumor Cells | Chaperonin-Containing TCP-1 | CCT | CTC

United States
Lawrence D Recht
Sanofi

Recruiting

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Glioblastoma | Malignant Glioma | Gliosarcoma | Glioblastoma With Primitive Neuronal Component | Oligodendroglial Component Present

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Meningioma | Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Von Hippel-Lindau Syndrome | Metastatic Well Differentiated Neuroendocrine Neoplasm | Somatostatin Positive Neoplastic Cells Present

United States
Gritstone bio, Inc.
Bristol-Myers Squibb

Completed

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Shared Neoantigen-Positive Solid Tumors

United States
Centre Oscar Lambret

Recruiting

Feasibility of a New Technology for Isolating Circulating Tumour Cells (CTC-SMMiL-E)

Ovarian Cancer | Hormone-resistant Prostate Cancer | Circulating Tumor Cell | HER2-positive Metastatic Breast Cancer

France
David Bushnell
National Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...

Active, not recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Tumor of the Lung | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1 | Neuroendocrine Tumor of Pancreas

United States
Prof. W. Janni

Completed

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs (DETECT III)

HER2-negative Metastatic Breast Cancer | HER2-positive Circulating Tumor Cells

Germany
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States
Takeda

Withdrawn

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Adult Solid Tumor | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Germ Cell Tumor | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative... and other conditions

United States
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States

Clinical Trials on NY-ESO-1 Positive Tumor Cells Present

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations